FDA: Martin Shkreli / Turing Pharmaceuticals Correspondence

Tony Webster filed this request with the Food and Drug Administration of the United States of America.
Tracking # 2015-10188
Status
Rejected

Communications

From: Tony Webster

To Whom It May Concern:

This is a request under the Freedom of Information Act. I hereby request the following records:

1) All correspondence or communication to, from, or regarding Martin Shkreli since January 1, 2008;
2) All correspondence or communication to, from, or regarding Turing Pharmaceuticals since January 1, 2008.

FEE WAIVER REQUEST: The requested documents will be made available to the general public, and this request is not being made for commercial purposes. Responsive records will be used for journalism purposes and will help increase the public's understanding of government activities regarding a notable person. In the event that fees cannot be waived, I would be grateful if you would inform me of the total charges in advance of fulfilling my request. I would prefer the request filled electronically, by e-mail attachment if available or CD-ROM if not.

Thank you in advance for your anticipated cooperation in this matter. I look forward to receiving your response to this request within 20 business days, as the statute requires.

Sincerely,
Tony Webster

From: Lee, Elizabeth J. (FDA)

Dear Mr. Webster,

I am returning your status inquiry from 1/20/2016. Please give me a call to discuss your FOI request, 2015-10188. I am available Monday - Friday from 9:00 am - 5 pm.

Request:
1) All correspondence or communication to, from, or regarding Martin Shkreli since
January 1, 2008;
2) All correspondence or communication to, from, or regarding Turing Pharmaceuticals
since January 1, 2008.

Thanks,

Elizabeth J. Lee
Lead Regulatory Counsel
FDA/CDER/ORP/Division of Information Disclosure Policy
301-796-3456 (direct)/301-796-3603 (main)/301-431-6351 (fax)
This e-mail message may contain information that is protected, privileged, or confidential, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. If you are not the intended recipient, any dissemination, distribution or copying is strictly prohibited. If you think you have received this e-mail message in error, please e-mail the sender immediately at elizabeth.lee@fda.hhs.gov.

From: Lee, Elizabeth J. (FDA)

Dear Mr. Webster,

I am following up on my email from 1/25/16.

Thanks,

Elizabeth J. Lee
Lead Regulatory Counsel
FDA/CDER/ORP/Division of Information Disclosure Policy
301-796-3456 (direct)/301-796-3603 (main)/301-431-6351 (fax)
This e-mail message may contain information that is protected, privileged, or confidential, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. If you are not the intended recipient, any dissemination, distribution or copying is strictly prohibited. If you think you have received this e-mail message in error, please e-mail the sender immediately at elizabeth.lee@fda.hhs.gov<mailto:elizabeth.lee@fda.hhs.gov>.

Files

There are no files associated with this request.